The estimated Net Worth of Mark Corrigan is at least $304 Tisíc dollars as of 2 August 2022. Mark Corrigan owns over 10,297 units of Wave Life Sciences stock worth over $42,498 and over the last 7 years he sold WVE stock worth over $1,956. In addition, he makes $259,093 as Independent Director at Wave Life Sciences.
Sign up
Mark Corrigan WVE stock SEC Form 4 insiders trading
Mark has made over 1 trades of the Wave Life Sciences stock since 2022, according to the Form 4 filled with the SEC. Most recently he sold 10,297 units of WVE stock worth $1,956 on 2 August 2022.
The largest trade he's ever made was selling 10,297 units of Wave Life Sciences stock on 2 August 2022 worth over $1,956. On average, Mark trades about 644 units every 0 days since 2017. As of 2 August 2022 he still owns at least 7,203 units of Wave Life Sciences stock.
You can see the complete history of Mark Corrigan stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mark Corrigan biography
Dr. Mark H.N. Corrigan., M.D. is Independent Director of the Company. Dr. Corrigan currently serves as the Chief Executive Officer of Correvio Pharma Corp., where he has worked since March 2019. Prior to joining Correvio, Dr. Corrigan was President of Research and Development at Tremeau Pharmaceuticals from 2016 to March 2019. Dr. Corrigan served as President and Chief Executive Officer of Zalicus, Inc. (formerly CombinatoRx) from 2010 to 2014. Prior to that time, from 2003 to 2009, Dr. Corrigan held the role of Executive Vice President, Research and Development at Sepracor Inc. From 2000 to 2003, Dr. Corrigan served as Group Vice President, Clinical Research & Experimental Medicine at Pharmacia Corporation. Prior to this, Dr. Corrigan held various roles at The Upjohn Company, The University of North Carolina, and the National Institute of Mental Health Center for Psychoneuroendocrinology in Adults and Children at Dorthea Dix Hospital. Dr. Corrigan currently serves as a member of the boards of directors of Correvio Pharma Corp., Nabriva Therapeutics, and Tremeau Pharmaceuticals, of which he is a co-founder. Dr. Corrigan holds an M.D. from the University of Virginia and received specialty training in psychiatry at Maine Medical Center and Cornell University. He received a Bachelor of Arts in Psychology from the University of Virginia.
What is the salary of Mark Corrigan?
As the Independent Director of Wave Life Sciences, the total compensation of Mark Corrigan at Wave Life Sciences is $259,093. There are 8 executives at Wave Life Sciences getting paid more, with Paul Bolno having the highest compensation of $3,581,530.
How old is Mark Corrigan?
Mark Corrigan is 62, he's been the Independent Director of Wave Life Sciences since 2019. There are 1 older and 17 younger executives at Wave Life Sciences. The oldest executive at Wave Life Sciences Ltd. is Koji Miura, 71, who is the Independent Director.
What's Mark Corrigan's mailing address?
Mark's mailing address filed with the SEC is C/O WAVE LIFE SCIENCES LTD.,, 733 CONCORD AVE., CAMBRIDGE, MA, 02138.
Insiders trading at Wave Life Sciences
Over the last 9 years, insiders at Wave Life Sciences have traded over $19,158,839 worth of Wave Life Sciences stock and bought 18,619,108 units worth $128,204,225 . The most active insiders traders include Plc Gsk, Capital Management, L.P.Ra ... a Capital Management, Llc Kol.... On average, Wave Life Sciences executives and independent directors trade stock every 43 days with the average trade being worth of $1,569,819. The most recent stock trade was executed by Paul Bolno on 21 August 2024, trading 48,366 units of WVE stock currently worth $279,555.
What does Wave Life Sciences do?
wave life sciences ltd. (nasdaq: wve) is utilizing its innovative and proprietary synthetic chemistry drug development platform to design, develop and commercialize stereopure nucleic acid therapeutics that precisely target the underlying cause of rare genetic diseases, delivering new treatment options for patients. given the unique versatility of its chemistry platform, wave’s pipeline spans multiple oligonucleotide modalities including antisense, exon-skipping and single-stranded rnai.
What does Wave Life Sciences's logo look like?
Complete history of Mark Corrigan stock trades at Nabriva Therapeutics Plc, Trevena Inc a Wave Life Sciences
Wave Life Sciences executives and stock owners
Wave Life Sciences executives and other stock owners filed with the SEC include:
-
Paul Bolno,
President, Chief Executive Officer, Director -
Christopher Francis,
Senior Vice President - Corporate Development, Head of Emerging Areas -
Michael Panzara,
Chief Medical Officer -
Chandra Vargeese,
Senior Vice President, Head of Drug Discovery -
Dr. Paul B. Bolno M.B.A., M.D., MBA,
Pres, CEO & Director -
Dr. Michael A. Panzara M.D., M.P.H., MPH,
Chief Medical Officer and Head of Therapeutics Discovery & Devel. -
Dr. Chandra Vargeese Ph.D.,
Chief Technology Officer -
Gregory Verdine,
Director -
Mark Corrigan,
Independent Director -
Amy Pott,
Independent Director -
Heidi Wagner,
Independent Director -
Christian Henry,
Independent Chairman of the Board -
Peter Kolchinsky,
Independent Director -
Ken Takanashi,
Independent Director -
Adrian Rawcliffe,
Independent Director -
Koji Miura,
Independent Director -
Kenneth Rhodes,
Senior Vice President - Therapeutics Discovery -
David Gaiero,
Interim Chief Financial Officer -
Kate Rausch,
Investor Relations -
Anne-Marie Li-Kwai-Cheung,
Sr. VP of Regulatory Affairs, Compliance & Policy -
Dr. Sridhar Vaddeboina Ph.D.,
Sr. VP of Chemistry, Manufacturing & Controls -
Jose Juves,
Sr. VP of Corp. Affairs & Patient Advocacy -
Jonathan Rosin,
Chief HR Officer -
Dr. Christopher Francis Ph.D.,
Sr. VP of Corp. Devel. & Head of Emerging Areas -
Linda Rockett J.D.,
Gen. Counsel -
Kyle B. Moran CFA,
CFO & Principal Accounting Officer -
Chris Francis,
See Remarks -
Plc Gsk,
10% owner -
Keith Regnante,
Chief Financial Officer -
Takeshi Wada,
Director -
Ken Shin Nippon Biomedical ...,
-
Masaharu Kagoshima Shinsang...,
-
Roberto Guerciolini,
See Remarks -
Masaharu Tanaka,
Director -
Peter Kolchinsky,
Director -
Capital Management, Llc Kol...,
-
Mark Baldry,
Chief Commerical Officer -
Capital Management, L.P.Ra ...,
-
Kyle Moran,
Chief Financial Officer -
Aik Na Tan,